Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload

Stephen C Nelson1, Jane M Hennessy, Elizabeth A McDonough

  • 1Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA. stephen.nelson@childrensmn.org

Insights

High-dose intravenous deferoxamine effectively manages iron overload in children needing frequent transfusions. This outpatient treatment is safe, practical, and well-tolerated, improving patient outcomes.

Area of Science:

  • Pediatric Hematology
  • Clinical Pharmacology

Background:

  • Iron overload is a significant complication for pediatric patients requiring chronic red blood cell transfusions.
  • Subcutaneous deferoxamine administration often faces challenges with patient compliance.

Purpose of the Study:

  • To evaluate the safety and efficacy of a very high-dose intravenous deferoxamine regimen in pediatric patients with iron overload.
  • To assess the practicality and tolerability of this intensive treatment protocol.

Main Methods:

  • Fourteen pediatric patients received intravenous deferoxamine at a high dose (15 mg/kg/h) over 48 hours, administered every 2 or 4 weeks.
  • The treatment duration averaged 18 months.
  • Outpatient administration without central venous catheter use was employed.

Main Results:

  • The intermittent very high-dose intravenous deferoxamine regimen was well-tolerated by the pediatric patients.
  • The treatment proved successful in effectively removing excess iron from the body.
  • The regimen was practical for outpatient administration.

Conclusions:

  • Intermittent very high-dose intravenous deferoxamine is a safe, practical, and effective strategy for managing iron overload in children.
  • This treatment approach offers a viable alternative for pediatric patients with transfusion-dependent anemias, improving compliance and iron chelation outcomes.